Optimal management of induction therapy with ATG in kidney allograft recipients

International Journal of Immunotherapy

Volumn 15, Issue 3-4, 1999, Pages 115-124

  Kaden, J ^a  

^a VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; PREDNISOLONE; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CADAVER KIDNEY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; SENSITIZATION; SURVIVAL TIME;

EID: 0033493069     PISSN: 02559625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Barth R.F., Southworth J., Burger G.M. Studies on heterologous antilymethylprednisolonehocyte and antithymocyte sera. J. Immunol., 101, 282, 1968.
2. James K., Milne J. The effect of antilymphocytic antibody on the primary immune response of mice to sheep erythrocytes, bovine serum albumin, and type III pneumo-coccus polysaccharide. Transplantation, 12, 109, 1971.
3. Reuben C., Sundaram K., Phondke G.P. Suppression of primary immune response by heterologous anti-lymphocytes sera. J. Immunol., 34, 223, 1978.
4. Ghaffar A., James K. The effect of individual ALG preparations on the immune response to type III polysaccharide antigen. J. Immunol., 26, 11, 1974.
5. Okumura K., Tada T., Ochiai T. Effect of antithymocyte serum on reaginic antibody formation in the rat. J. Immunol., 26, 257, 1974.
6. Möller G., Zukowski C.F. Heterologous antilymphocyte serum: Differential effect on antigen-sensitive and antibody-producing cells. Surgery, 64, 39, 1968.
7. Barth R.F. Studies on heterologous antilymphocyte and antithymocyte sera. J. Immunol., 103, 648, 1969.
8. Biesecker J.L., Fitch F.W., Rowley D.A., Stuart F.P. Cellular and humoral immunity after allogeneic transplantation in the rat. Tranplantation, 16, 441, 1973.
9. Finger H., Hof H., Wirsing C.-H., Emmerling P. Suppression of the secondary immune response by specific antibody, when given together with the secondary antigenic stimulus. Experientia, 33, 531, 1977.
10. Kaden J., Groth J., Oesterwitz H., Schröder K. Passives Enhancement allogener Rattennierentransplantate durch Antikörper gegen nylonadhärente Milzlymethylprednisolonehozyten. Z. Urol. u. Nephrol., 76, 413, 1983.
11. Kaden J., May G., Schönemann C., et al. Effect of ATG prophylaxis in sensitized and non-sensitized kidney graft recipients. Transplant Int., 5, 75, 1992.
12. Kaden J., May G., Müller P., Strobelt V., Groth J. Intraoperative T-Zelldepletion mittels ATG als erfolgversprechendes Therapiekonzept bei Nierentransplantatemethylprednisolonefängern. Transplant. Med., 7, 182, 1995.
13. Ippoliti G., Negri M., Abelli P., et al. Preoperative prophylactic OKT3 vs RATG. A randomized clinical study in heart transplant patients. Transplant Proc., 23, 2272, 1991.
14. Stratta R.J., Taylor R.J., Weide L.G., et al. A prospective randomized trial of OKT3 vs ATGAM induction therapy in pancreas transplant recipients. Transplant Proc., 28, 917, 1996.
15. von Woellwarth J., Behrend M., Schutt H.J., et al. Ergebnisse der Nierentransplantation bei immunologischen Risiko-patienten unter einer Dreifach-Therapie mit Mycophenolat-Mofetil. Tx. Med., 8, 50, Suppl. 1996.
16. Hourmant M., Bedrossian J., Durand D., et al. A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations. Transplantation, 62, 1565, 1996.
17. th World Cong. Transplant. Soc. Montreal, July 12-17, 1998, Abstract 1648, p. 319.
18. Nashan B., Moore R., Amlot P., Schmidt A.G., Abeywickrama K., Soulillou J.-P. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet, 350, 1193, 1997.
19. Vincenti F., Kirkman R., Light S., et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N. Eng. J. Med., 338, 161, 1998.
20. Contraras J.L., Wang P.X., Eckhoff D.E., et al. Peritransplant tolerance induction with anti-CD3-immunotoxin. Transplantation, 65, 1159, 1998.
21. Delmonico F.L., Cosimi A.B., Colvin R., et al. Murine OKT4A immunosuppression in cadaver donor renal allograft recipients. Transplantation, 63, 1243, 1997.
22. Schult T., Martin D., Heimes M., Klempnauer J., Buesing M. Tacrolimus/mycophenolate mofetil/steroid-based immunosuppression after pancreas-kidney transplantation with single shot antithymocyte globulin. Transplant Proc., 30, 1533, 1998.
23. Boucek M.M., Pietra B., Sondheimer H., et al. Anti-T-cell-antibody prophylaxis in children: Success with a novel combination strategy of mycophenolate mofetil and antithymocyte serum. Transplant Proc., 29, 16, 1997.
24. Hayasaka Y., Takahashi K., Yagisawa T., et al. Immunological evaluation on ATG-F of its antibody specificity and the effect on graft rejection. Proc. 28th Conf. Jap. Transplant Soc., Osaka, Sept. 24-26, 1992, p. 92.
25. Kaden J., May G., Müller P., et al. Intraoperative high-dose anti-T-lymphocyte globulin bolus in addition to triple-drug therapy improves kidney graft survival. Transplant Proc., 27, 1060, 1995.
26. Buelens C., Willems F., Delvaux A., et al. Interleukin-10 differentially regulates B7-1 (CD80) and B7-2 (CD86) expression on human peripheral blood dendritic cells. Eur. J. Immunol., 25, 2668, 1995.
27. Fuchs A.C., Granowitz E.V., Shapiro L., et al. Clinical, hematologic, and immunologic effects of interleukin-10 in humans. J. Clin Immunol., 16, 291, 1996.
28. th World Cong. Transplantation Soc., Montreal July 12-17, 1998, Abstract 417, p. 113.
29. Kuttler B., Lehmann M., Lacha J., Brock J., Jahn H.J. Anti-CD4 therapy induces a donor-specific, organ-nonspecific tolerance in allogeneic kidney graft recipients. Transplant Proc., 26, 728, 1994.
30. Risch K., Becker G., Graser E., et al. Inhibition of chronic rejection after kidney transplantation by anti-CD4 treatment. Transplant Proc., 29, 328, 1997.
31. Plain K.M., Fava L., Spinelli A., et al. Induction of tolerance with nondepleting anti-CD4 monoclonal antibodies is asociated with down-regulation of TH2 cytokines. Transplantation, 64, 1559. 1997.
32. Sharma L.C., Muirhead N., Lazarovits A.I. Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection: Analysis beyond 4 years. Transplant Proc., 29, 323, 1997.
33. Cavazzana-Calvo M., Sarnacki S., Haddad E., et al. Prevention of bone marrow and cardiac graft rejection in an H-2 haplotype disparate mouse combination by an anti-LFA-1 antibody. Transplantation, 59, 1576, 1995.
34. Nakakura E.K., Shorthouse R.A., Zheng B., McCabe S.M., Jardieu P.M., Morris R.E. Long-term survival of solid organ allografts by brief anti-lymphocyte function-associated antigen-1 monoclonal antibody monotherapy. Transplantation, 62, 547, 1996.
35. Lakkis F.G., Konieczny B.T., Saleem S., et al. Blocking the CD28-B7 T-cell costimulation pathway induces long-term cardiac allograft acceptance in the absence of IL-4. J. Immunol., 158, 2443, 1997.
36. Subbotin V., Sun H., Chen C., et al. Combined blockade of CD28/B7 and CD40/CD40L costimulatory pathways prevents the onset of chronic rejection. Transplant Proc., 30, 941, 1998.
37. Schaub M., Stadlbauer T.H.W., Chandraker A., Vella J.P., Turka L.A., Sayegh M.H. Comparative strategies to induce long-term graft acceptance in fully allogeneic renal versus cardiac allograft models by CD28-B7 T-cell costimulatory blockade: Role of thymus and spleen. J. Am. Soc. Nephrol., 9, 891, 1998.
38. Iwata T., Kamei Y., Esaki S., et al. Immunosuppression by anti-ICAM-1 and anti-LFA-1 monoclonal antibodies of free and vascularized skin allograft rejection. Immunobiol., 195, 160, 1996.
39. Woodward J.E., Bayer A.L., Chavin K.D., Boleza K.A , Baliga P. Anti-transferrin receptor monoclonal antibody. Transplantation, 65, 6. 1998.
40. Hong J.H., Sumrani N., Cacciarelli T.V., Distant D., Sommer B.G. Initiation of ALG pretransplant reduces the incidence of delayed renal allograft function. Transplant. Proc., 25, 581, 1993.
41. Ojo A.O., Wolfe R.A., Held P.J., Port F.K., Schmouder R.L. Delayed graft function: Risk factors and implications for renal allograft survival. Transplantation, 63, 968, 1997.
42. Lindholm A., Ohlman S., Albrechtsen D., Tufveson G., Persson H., Persson N.H. The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens. Transplantation, 56, 307, 1993.
43. Vanrenterghem Y.F.C. Acute rejection and renal allograft outcome. Nephrol. Dial. Transplant, 10, 29, 1995.
44. Evans R.W., Kitzmann D.J. An economic analysis of kidney transplantation. Surg. Clin. N.A., 78, 149, 1998.
45. Opelz G. (for the collaborative transplant study). Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Transplantation, 60, 1220, 1995.
46. Kaden J., Strobelt V., May G. Short- and long-term results after pretransplant high-dose single ATG-Fresenius bolus in cadaveric kidney transplantation. Transplant Proc., 30, 4011, 1998.